Schinkel A H, Roelofs E M, Borst P
Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam.
Cancer Res. 1991 May 15;51(10):2628-35.
We have cloned a human MDR3 complementary DNA, coding for a P-glycoprotein, into a mammalian expression vector and cotransfected it with a selectable marker into drug-sensitive human BRO melanoma cells. With low frequency we obtained stable, MDR3-expressing clones. Immunocytochemical and immunoblotting analysis of these clones using the monoclonal antibody C219 indicated that human MDR3 P-glycoprotein, like human MDR1 P-glycoprotein, was mainly localized in the plasma membrane and probably glycosylated. Although a significant fraction of the cells (5-10%) in one of the MDR3-expressing clones expressed as much P-glycoprotein as a clearly drug-resistant MDR1-transfected clone, we found no resistance against a range of drugs affected by multidrug resistance. The drugs tested included vincristine, colchicine, VP16-213, daunorubicin, doxorubicin, actinomycin D, and gramicidin D. We did not detect enhanced daunorubicin efflux either in any of the MDR3-expressing cells by fluorescence microscopy. Direct selection with vincristine, actinomycin D, gramicidin D, or daunorubicin of BRO cells transfected with expression constructs containing the regular MDR3 complementary DNA, or a complementary DNA representing a major MDR3 splice variant (C(-141)), likewise failed to yield resistant clones. Thus, although human MDR3 P-glycoprotein is highly similar to human MDR1 P-glycoprotein, we found no indications that it can transport drugs. We investigated the cross-reactivity of the monoclonal antibodies C219, C494, JSB-1, HYB-241, and MRK16, recognizing human MDR1 P-glycoprotein, with human MDR3 P-glycoprotein using immunocytochemistry and immunoblotting. Apart from monoclonal antibody C219, none of the monoclonal antibodies showed detectable cross-reactivity with human MDR3 P-glycoprotein. In our hands, monoclonal antibodies MRK16 and HYB-241 were most suitable for sensitive and specific cytochemical detection of human MDR1 P-glycoprotein.
我们已将编码一种P - 糖蛋白的人类MDR3互补DNA克隆到一个哺乳动物表达载体中,并将其与一个选择标记共转染到对药物敏感的人类BRO黑色素瘤细胞中。我们以低频率获得了稳定表达MDR3的克隆。使用单克隆抗体C219对这些克隆进行免疫细胞化学和免疫印迹分析表明,人类MDR3 P - 糖蛋白与人类MDR1 P - 糖蛋白一样,主要定位于质膜,并且可能进行了糖基化。尽管在一个表达MDR3的克隆中,有相当一部分细胞(5 - 10%)表达的P - 糖蛋白与一个明显耐药的转染了MDR1的克隆一样多,但我们发现这些细胞对一系列受多药耐药影响的药物没有耐药性。所测试的药物包括长春新碱、秋水仙碱、VP16 - 213、柔红霉素、阿霉素、放线菌素D和短杆菌肽D。通过荧光显微镜检查,我们在任何表达MDR3的细胞中均未检测到柔红霉素外排增强。用长春新碱、放线菌素D、短杆菌肽D或柔红霉素直接筛选转染了含有正常MDR3互补DNA或代表主要MDR3剪接变体(C(-141))的互补DNA的表达构建体的BRO细胞,同样未能产生耐药克隆。因此,尽管人类MDR3 P - 糖蛋白与人类MDR1 P - 糖蛋白高度相似,但我们没有发现它能够转运药物的迹象。我们使用免疫细胞化学和免疫印迹法研究了识别人类MDR1 P - 糖蛋白的单克隆抗体C219、C494、JSB - 1、HYB - 241和MRK16与人类MDR3 P - 糖蛋白的交叉反应性。除了单克隆抗体C219外,其他单克隆抗体均未显示出与人类MDR3 P - 糖蛋白可检测到的交叉反应性。在我们的实验中,单克隆抗体MRK16和HYB - 241最适合对人类MDR1 P - 糖蛋白进行灵敏且特异的细胞化学检测。